Slingshot members are tracking this event:
FDA Approves Merck’s (MRK) KEYTRUDA (pembrolizumab) for the Adjuvant Treatment of Patients with Melanoma with Involvement of Lymph Node(s) Following Complete Resection
Slingshot Insights Explained
Feb 19, 2019
Don’t see a project related to the catalyst you care about?
Related Keywords Keytruda, Pembrolizumab, Melanoma